Benzinga | Sep 2, 2021 07:01AM EDT

Zynerba Pharmaceuticals To Present At The Society For The Study Of Behavioural Phenotypes Conference 2021 On Sept. 9

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and oral presentation details of two sets of data at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021, which will be held virtually from September 9-10, 2021. A copy of the presentation slides will be made available on the Zynerba corporate website following each presentation at http://zynerba.com/publications/. Additional meeting information can be found on the SSBP website at https://ssbp.org.uk/.



Oral Presentation Details

Longer Term Tolerability and Efficacy of ZYN002 CannabidiolTitle: Transdermal Gel in Children and Adolescents with Autism Spectrum Disorder (ASD): An Open-Label Phase 2 Study (BRIGHT [ZYN2-CL-030])Session: Session 1Date: September 9, 2021Time: 5:15 a.m. ET A Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel inTitle: Children and Adolescents With Fragile X Syndrome [CONNECT-FX (ZYN2-CL-016)]Session: Session 4Date: September 10, 2021Time: 2:15 p.m. ET